Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry
Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry laboratories owned by NeoGenesis that enable the rapid screening of compounds that could be used to form new products. Epix hopes the deal will enable it to find new advanced MRI contrast agents.
New Study Assesses Benefits of High-Resolution Photon-Counting for Computed Tomography Angiography
October 10th 2024Researchers found that ultra-high resolution photon-counting significantly enhanced visualization of small vessels and facilitated improved reduction of blooming artifacts for head and neck computed tomography angiography (CTA) scans.
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.